Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 165

1.

Speciation and accumulation of Zn in sweetcorn kernels for genetic and agronomic biofortification programs.

Cheah ZX, Kopittke PM, Harper SM, Meyer G, O'Hare TJ, Bell MJ.

Planta. 2019 Jul;250(1):219-227. doi: 10.1007/s00425-019-03162-x. Epub 2019 Apr 12.

PMID:
30980245
2.

Identification and Characterization of AES-135, a Hydroxamic Acid-Based HDAC Inhibitor That Prolongs Survival in an Orthotopic Mouse Model of Pancreatic Cancer.

Shouksmith AE, Shah F, Grimard ML, Gawel JM, Raouf YS, Geletu M, Berger-Becvar A, de Araujo ED, Luchman HA, Heaton WL, Bakhshinyan D, Adile AA, Venugopal C, O'Hare T, Deininger MW, Singh SK, Konieczny SF, Weiss S, Fishel ML, Gunning PT.

J Med Chem. 2019 Mar 14;62(5):2651-2665. doi: 10.1021/acs.jmedchem.8b01957. Epub 2019 Mar 6.

PMID:
30776234
3.

Nuclear-Cytoplasmic Transport Is a Therapeutic Target in Myelofibrosis.

Yan D, Pomicter AD, Tantravahi S, Mason CC, Senina AV, Ahmann JM, Wang Q, Than H, Patel AB, Heaton WL, Eiring AM, Clair PM, Gantz KC, Redwine HM, Swierczek SI, Halverson BJ, Baloglu E, Shacham S, Khorashad JS, Kelley TW, Salama ME, Miles RR, Boucher KM, Prchal JT, O'Hare T, Deininger MW.

Clin Cancer Res. 2019 Apr 1;25(7):2323-2335. doi: 10.1158/1078-0432.CCR-18-0959. Epub 2018 Dec 18.

PMID:
30563936
4.

Does kernel position on the cob affect zeaxanthin, lutein and total carotenoid contents or quality parameters, in zeaxanthin-biofortified sweet-corn?

Calvo-Brenes P, Fanning K, O'Hare T.

Food Chem. 2019 Mar 30;277:490-495. doi: 10.1016/j.foodchem.2018.10.141. Epub 2018 Oct 31.

PMID:
30502175
5.

In situ analyses of inorganic nutrient distribution in sweetcorn and maize kernels using synchrotron-based X-ray fluorescence microscopy.

Cheah ZX, Kopittke PM, Harper SM, O'Hare TJ, Wang P, Paterson DJ, de Jonge MD, Bell MJ.

Ann Bot. 2019 Feb 15;123(3):543-556. doi: 10.1093/aob/mcy189.

PMID:
30357312
6.

Use of lung-protective strategies during one-lung ventilation surgery: a multi-institutional survey.

Kidane B, Choi S, Fortin D, O'Hare T, Nicolaou G, Badner NH, Inculet RI, Slinger P, Malthaner RA.

Ann Transl Med. 2018 Jul;6(13):269. doi: 10.21037/atm.2018.06.02.

7.

Autocrine Tnf signaling favors malignant cells in myelofibrosis in a Tnfr2-dependent fashion.

Heaton WL, Senina AV, Pomicter AD, Salama ME, Clair PM, Yan D, Bell RN, Gililland JM, Prchal JT, O'Hare T, Deininger MW.

Leukemia. 2018 Nov;32(11):2399-2411. doi: 10.1038/s41375-018-0131-z. Epub 2018 Apr 18.

8.

Similar expression profiles in CD34+ cells from chronic phase chronic myeloid leukemia patients with and without deep molecular responses to nilotinib.

Patel AB, Lange T, Pomicter AD, Conley CJ, Harrington CA, Reynolds KR, Kelley TW, O'Hare T, Deininger MW.

Oncotarget. 2018 Apr 3;9(25):17889-17894. doi: 10.18632/oncotarget.24954. eCollection 2018 Apr 3.

9.

Ongoing clonal evolution in chronic myelomonocytic leukemia on hypomethylating agents: a computational perspective.

Than H, Qiao Y, Huang X, Yan D, Khorashad JS, Pomicter AD, Kovacsovics TJ, Marth GT, O'Hare T, Deininger MW.

Leukemia. 2018 Sep;32(9):2049-2054. doi: 10.1038/s41375-018-0050-z. Epub 2018 Mar 27. No abstract available.

10.

Survey of Postoperative Regional Analgesia for Thoracoscopic Surgeries in Canada.

Shanthanna H, Moisuik P, O'Hare T, Srinathan S, Finley C, Paul J, Slinger P.

J Cardiothorac Vasc Anesth. 2018 Aug;32(4):1750-1755. doi: 10.1053/j.jvca.2018.01.003. Epub 2018 Jan 5.

PMID:
29402627
11.

A novel AGGF1-PDGFRb fusion in pediatric T-cell acute lymphoblastic leukemia.

Zabriskie MS, Antelope O, Verma AR, Draper LR, Eide CA, Pomicter AD, Tran TH, Druker BJ, Tyner JW, Miles RR, Graham JM, Hwang JY, Varley KE, Toydemir RM, Deininger MW, Raetz EA, O'Hare T.

Haematologica. 2018 Feb;103(2):e87-e91. doi: 10.3324/haematol.2017.165282. Epub 2017 Dec 28. No abstract available.

12.

Minimal Residual Disease Eradication in CML: Does It Really Matter?

Tantravahi SK, Guthula RS, O'Hare T, Deininger MW.

Curr Hematol Malig Rep. 2017 Oct;12(5):495-505. doi: 10.1007/s11899-017-0409-7. Review.

PMID:
28852963
13.

Late anastomotic breakdown with bevacizumab in colorectal cancers, a case-based review.

O'Hare T, McDermott R, Hannon R.

Ir J Med Sci. 2018 May;187(2):333-336. doi: 10.1007/s11845-017-1676-y. Epub 2017 Aug 29. Review.

PMID:
28852961
14.

Mechanisms of resistance to the BCR-ABL1 allosteric inhibitor asciminib.

Qiang W, Antelope O, Zabriskie MS, Pomicter AD, Vellore NA, Szankasi P, Rea D, Cayuela JM, Kelley TW, Deininger MW, O'Hare T.

Leukemia. 2017 Dec;31(12):2844-2847. doi: 10.1038/leu.2017.264. Epub 2017 Aug 18. No abstract available.

PMID:
28819281
15.

Mechanisms of Resistance to ABL Kinase Inhibition in Chronic Myeloid Leukemia and the Development of Next Generation ABL Kinase Inhibitors.

Patel AB, O'Hare T, Deininger MW.

Hematol Oncol Clin North Am. 2017 Aug;31(4):589-612. doi: 10.1016/j.hoc.2017.04.007. Review.

16.

Combined STAT3 and BCR-ABL1 inhibition induces synthetic lethality in therapy-resistant chronic myeloid leukemia.

Eiring AM, Page BDG, Kraft IL, Mason CC, Vellore NA, Resetca D, Zabriskie MS, Zhang TY, Khorashad JS, Engar AJ, Reynolds KR, Anderson DJ, Senina A, Pomicter AD, Arpin CC, Ahmad S, Heaton WL, Tantravahi SK, Todic A, Colaguori R, Moriggl R, Wilson DJ, Baron R, O'Hare T, Gunning PT, Deininger MW.

Leukemia. 2017 May;31(5):1253-1254. doi: 10.1038/leu.2017.14. No abstract available.

PMID:
28465516
17.

Post-traumatic Stress and Trauma-Related Subjective Distress: Comparisons Among Hispanics, African-Americans, and Whites with Severe Mental Illness.

O'Hare T, Shen C, Sherrer MV.

Community Ment Health J. 2017 Oct;53(7):778-781. doi: 10.1007/s10597-017-0097-8. Epub 2017 Feb 6.

PMID:
28168433
18.

A Retrospective Cohort Study of Total Colonic Aganglionosis: Is the Appendix a Reliable Diagnostic Tool?

O'Hare T, McDermott M, O'Sullivan M, Dicker P, Antao B.

J Neonatal Surg. 2016 Oct 10;5(4):44. eCollection 2016 Oct-Dec.

19.

Rapid conversion of chronic myeloid leukemia to chronic myelomonocytic leukemia in a patient on imatinib therapy.

Khorashad JS, Tantravahi SK, Yan D, Mason CC, Qiao Y, Eiring AM, Gligorich K, Hein T, Pomicter AD, Reid AG, Kelley TW, Marth GT, O'Hare T, Deininger MW.

Leukemia. 2016 Nov;30(11):2275-2279. doi: 10.1038/leu.2016.218. Epub 2016 Aug 2. No abstract available.

20.

Optimizing Pain and Rehabilitation After Knee Arthroplasty: A Two-Center, Randomized Trial.

Choi S, O'Hare T, Gollish J, Paul JE, Kreder H, Thorpe KE, Katz JD, Mamdani M, Moisiuk P, McCartney CJ.

Anesth Analg. 2016 Nov;123(5):1316-1324.

PMID:
27749351
21.

A Decade of Nilotinib and Dasatinib: From In Vitro Studies to First-Line Tyrosine Kinase Inhibitors.

O'Hare T.

Cancer Res. 2016 Oct 15;76(20):5911-5913. No abstract available.

22.

Sensitivity Analysis of the NPM-ALK Signalling Network Reveals Important Pathways for Anaplastic Large Cell Lymphoma Combination Therapy.

Buetti-Dinh A, O'Hare T, Friedman R.

PLoS One. 2016 Sep 26;11(9):e0163011. doi: 10.1371/journal.pone.0163011. eCollection 2016.

23.

Avian Leukosis Virus Activation of an Antisense RNA Upstream of TERT in B-Cell Lymphomas.

Nehyba J, Malhotra S, Winans S, O'Hare TH, Justice J 4th, Beemon K.

J Virol. 2016 Sep 29;90(20):9509-17. doi: 10.1128/JVI.01127-16. Print 2016 Oct 15.

24.

Ultrasensitive proteomic quantitation of cellular signaling by digitized nanoparticle-protein counting.

Jacob T, Agarwal A, Ramunno-Johnson D, O'Hare T, Gönen M, Tyner JW, Druker BJ, Vu TQ.

Sci Rep. 2016 Jun 20;6:28163. doi: 10.1038/srep28163.

25.

A role for FOXO1 in BCR-ABL1-independent tyrosine kinase inhibitor resistance in chronic myeloid leukemia.

Wagle M, Eiring AM, Wongchenko M, Lu S, Guan Y, Wang Y, Lackner M, Amler L, Hampton G, Deininger MW, O'Hare T, Yan Y.

Leukemia. 2016 Jul;30(7):1493-501. doi: 10.1038/leu.2016.51. Epub 2016 Mar 8.

26.

Disarming an Electrophilic Warhead: Retaining Potency in Tyrosine Kinase Inhibitor (TKI)-Resistant CML Lines While Circumventing Pharmacokinetic Liabilities.

Ali AM, Gómez-Biagi RF, Rosa DA, Lai PS, Heaton WL, Park JS, Eiring AM, Vellore NA, de Araujo ED, Ball DP, Shouksmith AE, Patel AB, Deininger MW, O'Hare T, Gunning PT.

ChemMedChem. 2016 Apr 19;11(8):850-61. doi: 10.1002/cmdc.201600021. Epub 2016 Mar 30.

27.

Lifetime Physical and Sexual Abuse and Self-Harm in Women With Severe Mental Illness.

O'Hare T, Shen C, Sherrer MV.

Violence Against Women. 2016 Sep;22(10):1211-27. doi: 10.1177/1077801215622576. Epub 2015 Dec 29.

PMID:
26719079
28.

A Novel Crizotinib-Resistant Solvent-Front Mutation Responsive to Cabozantinib Therapy in a Patient with ROS1-Rearranged Lung Cancer.

Drilon A, Somwar R, Wagner JP, Vellore NA, Eide CA, Zabriskie MS, Arcila ME, Hechtman JF, Wang L, Smith RS, Kris MG, Riely GJ, Druker BJ, O'Hare T, Ladanyi M, Davare MA.

Clin Cancer Res. 2016 May 15;22(10):2351-8. doi: 10.1158/1078-0432.CCR-15-2013. Epub 2015 Dec 16.

29.

Age-related mutations and chronic myelomonocytic leukemia.

Mason CC, Khorashad JS, Tantravahi SK, Kelley TW, Zabriskie MS, Yan D, Pomicter AD, Reynolds KR, Eiring AM, Kronenberg Z, Sherman RL, Tyner JW, Dalley BK, Dao KH, Yandell M, Druker BJ, Gotlib J, O'Hare T, Deininger MW.

Leukemia. 2016 Apr;30(4):906-13. doi: 10.1038/leu.2015.337. Epub 2015 Dec 9.

30.

Extreme mutational selectivity of axitinib limits its potential use as a targeted therapeutic for BCR-ABL1-positive leukemia.

Zabriskie MS, Eide CA, Yan D, Vellore NA, Pomicter AD, Savage SL, Druker BJ, Deininger MW, O'Hare T.

Leukemia. 2016 Jun;30(6):1418-21. doi: 10.1038/leu.2015.318. Epub 2015 Nov 19. No abstract available.

31.

Structural insight into selectivity and resistance profiles of ROS1 tyrosine kinase inhibitors.

Davare MA, Vellore NA, Wagner JP, Eide CA, Goodman JR, Drilon A, Deininger MW, O'Hare T, Druker BJ.

Proc Natl Acad Sci U S A. 2015 Sep 29;112(39):E5381-90. doi: 10.1073/pnas.1515281112. Epub 2015 Sep 8.

32.

β-Catenin is required for intrinsic but not extrinsic BCR-ABL1 kinase-independent resistance to tyrosine kinase inhibitors in chronic myeloid leukemia.

Eiring AM, Khorashad JS, Anderson DJ, Yu F, Redwine HM, Mason CC, Reynolds KR, Clair PM, Gantz KC, Zhang TY, Pomicter AD, Kraft IL, Bowler AD, Johnson K, Partlin MM, O'Hare T, Deininger MW.

Leukemia. 2015 Dec;29(12):2328-37. doi: 10.1038/leu.2015.196. Epub 2015 Jul 23.

33.

Limited efficacy of BMS-911543 in a murine model of Janus kinase 2 V617F myeloproliferative neoplasm.

Pomicter AD, Eiring AM, Senina AV, Zabriskie MS, Marvin JE, Prchal JT, O'Hare T, Deininger MW.

Exp Hematol. 2015 Jul;43(7):537-45.e1-11. doi: 10.1016/j.exphem.2015.03.006. Epub 2015 Apr 24.

34.

Lifetime abuse and self-harm in people with severe mental illness: A structural equation model.

O'Hare T, Shen C, Sherrer MV.

Psychol Trauma. 2015 Jul;7(4):348-55. doi: 10.1037/tra0000016. Epub 2015 Apr 13.

PMID:
25866963
35.

A coiled-coil mimetic intercepts BCR-ABL1 dimerization in native and kinase-mutant chronic myeloid leukemia.

Woessner DW, Eiring AM, Bruno BJ, Zabriskie MS, Reynolds KR, Miller GD, O'Hare T, Deininger MW, Lim CS.

Leukemia. 2015 Aug;29(8):1668-75. doi: 10.1038/leu.2015.53. Epub 2015 Feb 27.

36.

Chronic myeloid leukemia: advances in understanding disease biology and mechanisms of resistance to tyrosine kinase inhibitors.

Eide CA, O'Hare T.

Curr Hematol Malig Rep. 2015 Jun;10(2):158-66. doi: 10.1007/s11899-015-0248-3. Review.

37.

Radotinib is an effective inhibitor of native and kinase domain-mutant BCR-ABL1.

Zabriskie MS, Vellore NA, Gantz KC, Deininger MW, O'Hare T.

Leukemia. 2015 Sep;29(9):1939-42. doi: 10.1038/leu.2015.42. Epub 2015 Feb 13. No abstract available.

38.

Zeaxanthin biofortification of sweet-corn and factors affecting zeaxanthin accumulation and colour change.

O'Hare TJ, Fanning KJ, Martin IF.

Arch Biochem Biophys. 2015 Apr 15;572:184-187. doi: 10.1016/j.abb.2015.01.015. Epub 2015 Jan 28.

PMID:
25637659
39.

shRNA library screening identifies nucleocytoplasmic transport as a mediator of BCR-ABL1 kinase-independent resistance.

Khorashad JS, Eiring AM, Mason CC, Gantz KC, Bowler AD, Redwine HM, Yu F, Kraft IL, Pomicter AD, Reynolds KR, Iovino AJ, Zabriskie MS, Heaton WL, Tantravahi SK, Kauffman M, Shacham S, Chenchik A, Bonneau K, Ullman KS, O'Hare T, Deininger MW.

Blood. 2015 Mar 12;125(11):1772-81. doi: 10.1182/blood-2014-08-588855. Epub 2015 Jan 8.

40.

STAT3 as a mediator of BCR-ABL1-independent resistance in chronic myeloid leukemia.

Eiring AM, Kraft IL, Page BD, O'Hare T, Gunning PT, Deininger MW.

Leuk Suppl. 2014 Dec;3(Suppl 1):S5-6. doi: 10.1038/leusup.2014.3. Epub 2014 Dec 17. No abstract available.

41.

BCR-ABL1 promotes leukemia by converting p27 into a cytoplasmic oncoprotein.

Agarwal A, Mackenzie RJ, Besson A, Jeng S, Carey A, LaTocha DH, Fleischman AG, Duquesnes N, Eide CA, Vasudevan KB, Loriaux MM, Firpo E, Cortes JE, McWeeney S, O'Hare T, Roberts JM, Druker BJ, Deininger MW.

Blood. 2014 Nov 20;124(22):3260-73. doi: 10.1182/blood-2013-04-497040. Epub 2014 Oct 7.

42.

Combined STAT3 and BCR-ABL1 inhibition induces synthetic lethality in therapy-resistant chronic myeloid leukemia.

Eiring AM, Page BDG, Kraft IL, Mason CC, Vellore NA, Resetca D, Zabriskie MS, Zhang TY, Khorashad JS, Engar AJ, Reynolds KR, Anderson DJ, Senina A, Pomicter AD, Arpin CC, Ahmad S, Heaton WL, Tantravahi SK, Todic A, Moriggl R, Wilson DJ, Baron R, O'Hare T, Gunning PT, Deininger MW.

Leukemia. 2015 Mar;29(3):586-597. doi: 10.1038/leu.2014.245. Epub 2014 Aug 19. Erratum in: Leukemia. 2017 May;31(5):1253-1254.

43.

BCR-ABL1 compound mutations combining key kinase domain positions confer clinical resistance to ponatinib in Ph chromosome-positive leukemia.

Zabriskie MS, Eide CA, Tantravahi SK, Vellore NA, Estrada J, Nicolini FE, Khoury HJ, Larson RA, Konopleva M, Cortes JE, Kantarjian H, Jabbour EJ, Kornblau SM, Lipton JH, Rea D, Stenke L, Barbany G, Lange T, Hernández-Boluda JC, Ossenkoppele GJ, Press RD, Chuah C, Goldberg SL, Wetzler M, Mahon FX, Etienne G, Baccarani M, Soverini S, Rosti G, Rousselot P, Friedman R, Deininger M, Reynolds KR, Heaton WL, Eiring AM, Pomicter AD, Khorashad JS, Kelley TW, Baron R, Druker BJ, Deininger MW, O'Hare T.

Cancer Cell. 2014 Sep 8;26(3):428-442. doi: 10.1016/j.ccr.2014.07.006. Epub 2014 Aug 14.

44.

Sudden losses and negative appraisal in people with severe mental illness.

O'Hare T, Sherrer MV, Shen C.

Am J Orthopsychiatry. 2014 Nov;84(6):664-73. doi: 10.1037/ort0000014. Epub 2014 Aug 11.

PMID:
25110974
45.

The effect of lycopene on the PI3K/Akt signalling pathway in prostate cancer.

Chen J, O'Donoghue A, Deng YF, Zhang B, Kent F, O'Hare T.

Anticancer Agents Med Chem. 2014;14(6):800-5. Review.

PMID:
24851879
46.

Lifetime trauma and suicide attempts in people with severe mental illness.

O'Hare T, Shen C, Sherrer M.

Community Ment Health J. 2014 Aug;50(6):673-80. doi: 10.1007/s10597-013-9658-7. Epub 2013 Nov 27.

PMID:
24282033
47.

Integrating in vitro sensitivity and dose-response slope is predictive of clinical response to ABL kinase inhibitors in chronic myeloid leukemia.

Vainstein V, Eide CA, O'Hare T, Shukron O, Druker BJ.

Blood. 2013 Nov 7;122(19):3331-4. doi: 10.1182/blood-2012-08-452409. Epub 2013 Sep 23.

48.

Kinase inhibitor therapy in CML: it's what's inside that counts.

Eide CA, Druker BJ, O'Hare T.

Oncotarget. 2013 Sep;4(9):1332-3. No abstract available.

49.

What challenges remain in chronic myeloid leukemia research?

Carella AM, Branford S, Deininger M, Mahon FX, Saglio G, Eiring A, Khorashad J, O'Hare T, Goldman JM.

Haematologica. 2013 Aug;98(8):1168-72. doi: 10.3324/haematol.2013.090381. No abstract available.

50.

KIT signaling governs differential sensitivity of mature and primitive CML progenitors to tyrosine kinase inhibitors.

Corbin AS, O'Hare T, Gu Z, Kraft IL, Eiring AM, Khorashad JS, Pomicter AD, Zhang TY, Eide CA, Manley PW, Cortes JE, Druker BJ, Deininger MW.

Cancer Res. 2013 Sep 15;73(18):5775-86. doi: 10.1158/0008-5472.CAN-13-1318. Epub 2013 Jul 25.

Supplemental Content

Loading ...
Support Center